| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T482 |
0-116 |
Sentence |
denotes |
Atovaquone is an orally active, synthetic hydroxy-naphthoquinone derivative (Figure S6) with antiparasitic activity. |
| T483 |
117-144 |
Sentence |
denotes |
It was approved by the U.S. |
| T484 |
145-204 |
Sentence |
denotes |
FDA in 1992 against Pneumocystis jirovecii pneumonia [215]. |
| T485 |
205-308 |
Sentence |
denotes |
It has also been used to prevent and/or treat toxoplasmosis, malaria, and babesiosis [216,217,218,219]. |
| T486 |
309-499 |
Sentence |
denotes |
Mechanistically, it inhibits the electron transport chain in mitochondria, leading to the inhibition of critical metabolic enzymes important for the synthesis of nucleic acids and ATP [220]. |
| T487 |
500-729 |
Sentence |
denotes |
It is being evaluated in the U.S. alone (NCT04456153; n = 60) or in combination with azithromycin in an open-label, non-randomized study in COVID-19 patients at HonorHealth Clinical Research Institute, U.S. (NCT04339426; n = 25). |
| T488 |
730-836 |
Sentence |
denotes |
One potential mechanism of action for atovaquone pertaining to SARS-CoV-2 is the inhibition of Mpro [221]. |
| T489 |
837-906 |
Sentence |
denotes |
Another computational study suggested that it may inhibit RdRp [169]. |
| T490 |
907-987 |
Sentence |
denotes |
Importantly, these computational studies are yet to be experimentally confirmed. |
